MedTrace Logo

Real World Adherence of PCSK9 Targeted Therapy

NCT07468500 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 3600

Last updated 2026-03-20

No results posted yet for this study

Summary

Retrospective observational cohort study to compare medication adherence at 12 months between patients in Japan with dyslipidemia and/or hypercholesterolemia (familial and non-familial hypercholesterolemia) who newly initiate inclisiran versus those who newly initiate evolocumab.

Conditions

  • Dyslipidemia, Hypercholesterolemia

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-30
Primary Completion
2026-07-30
Completion
2026-07-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07468500 on ClinicalTrials.gov